Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01955668 · ClinicalTrials.gov registry record · Phase 1
AZD6738 First Time in Patient Multiple Ascending Dose Study
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT01955668 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 2 participants.
The verdict
NCT01955668, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
In Part A to investigate the safety and tolerability of AZD6738 when given orally to patients with relapsed/refractory CLL, PLL or B cell lymphoma. In Part B to investigate the safety and tolerability of AZD6738 when given orally to patients with prospectively identified 11q deleted or ATM deficient, relapsed/refractory CLL
Interventions
- DRUG Administration of AZD6738
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2013-11 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01955668
The ClinicalTrials.gov registry entry for NCT01955668 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Administration of AZD6738 is the first listed.
NCT01955668 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01955668 about?
NCT01955668 is a clinical study titled "AZD6738 First Time in Patient Multiple Ascending Dose Study". In Part A to investigate the safety and tolerability of AZD6738 when given orally to patients with relapsed/refractory CLL, PLL or B cell lymphoma. In Part B to investigate the safety and tolerability of AZD6738 when given orally to patients with prospectively identified 11q deleted or ATM deficien...
What is the current status of trial NCT01955668?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2013-11. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01955668?
The interventions under investigation include: Administration of AZD6738 (DRUG).
Who is sponsoring clinical trial NCT01955668?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.